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Abstract 26 
Nevirapine single dose (sd-NVP) and extended NVP prophylaxis are widely used in 27 
resource-constrained settings to prevent vertical HIV-1 transmission. 28 
We assessed the pharmacokinetics of sd-NVP in 62 HIV-1 positive Ugandan pregnant 29 
woman and their newborns, taking sd-NVP prophylaxis to prevent mother-to-child HIV-1 30 
transmission. Based on this data we developed a mathematical model system to 31 
quantify the impact of different sd-NVP regimens at delivery and extended infant NVP 32 
prophylaxis (6, 14, 21, 26, 52, 78, 102 weeks) on the 2 year risk of HIV-1 transmission 33 
and development of drug resistance in mothers and their breast-fed infants. 34 
Pharmacokinetic parameter estimates and model-predicted HIV-1 transmission rates 35 
were very consistent with other studies. Predicted 2 year HIV-1 transmission risks were 36 
37.5% without prophylaxis, 31.7% for newborn sd-NVP, 20.5% for maternal sd-NVP and 37 
22.3% for maternal/newborn sd-NVP. Maternal sd-NVP reduced newborn infection 38 
predominately by trans-placental exchange, providing protective NVP concentrations to 39 
the newborn at delivery, than by maternal viral load reduction. Drug resistance was 40 
frequently selected in HIV-1 positive mothers after maternal sd-NVP. 41 
Extended newborn NVP prophylaxis further decreased HIV-1 transmission risks but 42 
indicated an overall decline in cost-effectiveness for increasing durations of newborn 43 
prophylaxis. Additionally, the total number of newborn infections with resistant virus was 44 
not increased by extended newborn NVP prophylaxis. 45 
The developed mathematical modeling framework successfully predicted the risk of HIV-46 
1 transmission and resistance development and can be adapted to other drugs/drug 47 
combinations to a priori assess their potential in reducing vertical HIV-1 transmission 48 
and resistance spread. 49 
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Introduction 50 
HIV-1 infection remains a serious health care problem worldwide. In 2009, 51 
approximately 370,000 children became infected with HIV-1 (54). Mother-to-child 52 
transmission rates of HIV-1 in untreated breastfeeding populations in resource-limited 53 
settings ranged from 25% to 48%, accounting for the vast majority of pediatric AIDS (13). 54 
Vertical transmission of HIV-1 may occur during pregnancy (5%-10%), during birth 55 
(10%-20%), and via breastfeeding (10%-20%) (13). 56 
Intrapartum and newborn single dose nevirapine (NVP) significantly reduce transmission 57 
of HIV-1 from the mother to the child (24) and are essential components of HIV-1 58 
prevention strategies in many resource-constrained settings (58-59). However, the exact 59 
mechanism of HIV-1 prevention by NVP during intrapartum transmission remains 60 
unknown. Furthermore, owing to its long half-life, NVP frequently selects drug resistant 61 
viral strains in HIV-infected mothers (18, 23), which can compromise the efficacy of 62 
follow-up maternal and newborn antiretroviral treatment (ART) (9, 26, 30, 41). 63 
In many resource-constrained settings, breastfeeding is critical for infant survival (60). 64 
Reduction of HIV-1 transmission by short-course antiviral prophylaxis is frequently 65 
impaired by subsequent infection during the breastfeeding period (25, 44). Extended 66 
newborn NVP prophylaxis has shown to reduce HIV-1 transmission via breastfeeding (3, 67 
7, 28, 40) and current WHO guidelines for the prevention of mother-to-child transmission 68 
recommend the use of NVP throughout the entire breastfeeding period (59), which can 69 
be as long as 2 years. Clinical trial data on extended prophylactic newborn NVP are 70 
currently only available for durations of 6 weeks and 6 months (3, 11, 40). However, to 71 
evaluate the effectiveness of extended newborn NVP, a quantification of the HIV-1 72 
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transmission risks after different durations of extended NVP prophylaxis in newborns is 73 
required. 74 
In the present study, NVP plasma data of 62 Ugandan mothers and newborns who took 75 
NVP single dose prophylaxis were simultaneously analyzed in a single integrated 76 
population pharmacokinetic model for both populations; the present work extends a 77 
previously published pharmacokinetic study, which analyzed woman and newborn NVP 78 
concentrations separately (29). The aim of this work was to combine pharmacokinetic 79 
and pharmacodynamic analysis by developing a single mathematical modeling 80 
framework. The framework should be used to predict the impact of various single and 81 
extended NVP-based prophylaxis regimens on the cumulative risk of vertical HIV-1 82 
transmission and on selection of NVP-resistant virus. 83 
Methods 84 
Patient Characteristics and Study Design 85 
During a program for the prevention of mother-to-child transmission of HIV-1 in western 86 
Uganda, 62 HIV-1 positive pregnant women and their newborns were enrolled for 87 
pharmacokinetic (PK) analysis after they had given informed consent and delivered at 88 
Fort Portal District Hospital (Fort Portal, Kabarole District, western Uganda). Pregnant 89 
women received a single 200 mg NVP tablet at onset of labor and newborns received 90 
2 mg/kg NVP syrup orally within 72 h after birth (29). Ethical approval was obtained from 91 
the Uganda National Council for Science and Technology. 92 
Median age and body weight of the pregnant women were 26 years and 56 kg [range: 93 
16-39 yrs; 42-84 kg], respectively. Newborns had a median body weight of 3.1 kg [range: 94 
2.0-3.9 kg]. The median time period passed between NVP intake of pregnant women 95 
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and birth was 5.1 h [range: 0.3-24.8 h]. The median time interval between birth and NVP 96 
administration to the newborn was 0.9 h [range: 0.1-40.6 h] and 8.5 h [range: 1.3-46 h] 97 
from NVP intake of the pregnant women until the NVP administration to the newborns 98 
(29). 99 
For PK analysis, a total of 113 plasma samples from mothers and newborns were 100 
collected over three time periods, i.e. delivery, week 1 and week 2. The geometric mean 101 
NVP concentration-time profile was previously presented (29). Here we illustrate the 102 
dispersion of the individual plasma concentrations over time for the same population 103 
(Figure 1A). NVP concentrations were determined by a validated LC/tandem-mass-104 
spectrometry method according to the criteria set by the FDA (FDA-Guideline, (29, 49)). 105 
Pharmacokinetic Analysis 106 
Based on the previously established pharmacokinetic models and data (29), an 107 
integrated population pharmacokinetic model was developed to simultaneously analyze 108 
NVP plasma data of mothers and newborns. 109 
For population PK data analysis the nonlinear mixed effects modeling approach 110 
implemented in the software program NONMEMTM (Icon development solutions, version 111 
VI, 1st update, 2006) was chosen due to sparse data situation. The pharmacokinetic 112 
model was parameterized in terms of clearance(s) (CL) and volumes(s) of distribution (V) 113 
using the PREDPP subroutines (FOCE with interaction, ADVAN6 TOL5) supplied in 114 
NONMEMTM. The model building process was guided by changes in the objective 115 
function value of nested models provided by NONMEMTM, by precision of the PK 116 
parameter estimates (relative standard errors, RSE) and by basic goodness of fit (GOF) 117 
plots. Model-based simulations for visual predictive checks (VPC) were performed by 118 
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NONMEMTM (n=1000 simulations) and the statistics of 5th, median and 95th percentile 119 
were calculated using R, version 2.9. 120 
The schematic structure of the final PK model for maternal and newborn data is 121 
presented in Figure 1 B. Due to the difference in drug transport processes, solid lines 122 
represent those occurring continuously over the whole time and dashed lines only those 123 
before delivery except K34 which occurs only after delivery. The NVP absorption rate 124 
constants for pregnant women (KA) and newborns (K34) were fixed to 1.34 h-1, 125 
respectively, due to no available data during the absorption process. Prior published 126 
values of absorption rates varied between 0.013 h-1 and 3.81 h-1 (median: 1.3 h-1) (4, 12, 127 
17, 27). 128 
Maternal plasma concentrations were associated to the central compartment with the 129 
volume of distribution V2 and fetal/newborn concentrations to the peripheral 130 
compartment with the volume of distribution V4. After delivery, but before the NVP 131 
administration to newborns, significant NVP concentrations were detected in the plasma 132 
of newborns. Considering the placenta-permeability of NVP (37, 39), we implemented a 133 
trans-placental exchange of NVP between pregnant woman and fetus (PCL) before the 134 
time of delivery (dashed lines in Figure 1 B). The ratio of NVP plasma concentrations 135 
between fetus and pregnant women was described by a partition coefficient, PCM. NVP 136 
elimination from the central compartment (related to the plasma of mothers) and the 137 
peripheral compartment (related to the plasma concentration in the fetus/newborn) were 138 
described by the PK parameters CL1 and CL2, respectively. 139 
For the predictive performance of the final PK model a visual predictive check (VPC) is 140 
depicted in Figure 1 C-D. The dashed lines represent the 5th and 95th model-simulated 141 
percentiles and solid lines represent the model-simulated median of NVP concentrations. 142 
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The VPC of mother plasma (Figure 1 C) and newborn plasma data (Figure 1 D) revealed 143 
sufficient model predictive performance for the general trend. Overall, the model-144 
predicted variability was sufficient for mothers and newborns and resembled the 145 
variability in the observed data. 146 
HIV-1 Dynamics Model 147 
In order to quantify the impact of NVP prophylaxis on virus transmission, we adapted the 148 
virus dynamics model presented in (56) by discarding the longer lived cell types 149 
(representing macrophages and latently infected T-cells), as they do not impact the 150 
observed viral dynamics after short course maternal NVP. The utilized model of HIV-1 151 
dynamics and mother-to-child transmission is depicted in Figure 2 A. 152 
Briefly, the mathematical model of virus dynamics and mutation comprises T-cells T , 153 
free virus V , early infected T-cells 1T  (after reverse transcription but before viral 154 
genomic integration) and productively infected T-cells 2T  (after viral genomic integration). 155 
The average rate of change of the different T-cell species and the number of viruses is 156 
given by the following system of ordinary differential equations: 157 
 T PIC 1
d T = ( ) T ( , ) V( ) T T ( )
d i i
t i t i i
t
λ δ β δ− ⋅ − ⋅ ⋅ + ⋅∑ ∑  (1) 158 
 1 1 T1 T PIC
d T ( ) = ( , ) V( ) T T ( ) ( )
d j ij
i p j t j i k
t
β δ δ→ ⋅ ⋅ ⋅ − ⋅ + +∑  (2) 159 
 2 T 1 2 T2
d T ( ) = T ( ) T ( )
d
i k i i
t
δ⋅ − ⋅  (3) 160 
 2 V
d V( ) = N T ( ) V CL ( )
d
i i t
t
⋅ − ⋅  (4) 161 
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In summary, free virus V  of strain i  can infect T-cells with infection rate constant β , 162 
which encompasses all steps from target cell binding, fusion, to reverse transcription, 163 
resulting in early infected cells 1T , which turn into productively infected cells 2T  by 164 
provirus translocation into the nucleus and integration with rate Tk . 2T  produce new 165 
virus V  with the rate constant N (on average 1000 virions/day/cell (47)). Native, early 166 
infected and productively infected T-cells are degraded with rate constants Tδ , T1δ  and 167 
T2
δ , respectively. In early infected cells 1T (prior to proviral integration) essential 168 
components of the pre-integration complex can be degraded with rate constant PICδ , 169 
returning the cell to an uninfected stage T (56). Native T-cells are produced with rate 170 
constant ( )tλ  and free virus V  is cleared with rate VCL ( )t  by the immune system. We 171 
assumed that the rate constants ( )tλ and VCL ( )t are constant for the HIV-infected 172 
mothers, whereas they were considered time-dependent for the newborn, due to 173 
immune system development and growth. A derivation of the parameters ( )tλ  (newborn) 174 
and VCL ( )t  (newborn) is provided in the supplementary text S1. All model parameters 175 
are displayed in Table 1. 176 
Viral Mutation: 177 
HIV can aquire drug resistance by mutation during the process of reverse transcription 178 
(comprised in parameter β  in the model). The probability that a specific mutation occurs 179 
during the process of reverse transcription has been quantified ex vivo to be 180 
5
= 2.16 10µ −⋅ (per base and reverse transcription process) (31). A single genomic point 181 
mutation inducing a change at the protein level, e.g. position Y181 -> 181C (Y181C) will 182 
therefore occur with probability µ  during reverse transcription, whereas with probability 183 
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(1 )µ−  this specific mutation will not occur. In our model, 2 specific sites L are regarded 184 
to undergo mutation; resulting in the K103N and the Y181C change in the reverse 185 
transcriptase enzyme, respectively. As an example, the probability that the wild type 186 
virus wt  will neither be mutated at one of the 2 sites is 2(1 )wt wtp µ→ = − . The probabilities 187 
that precicely one mutation occurs is given by 181 (1 )wt Y Cp µ µ→ = − ⋅  and the probability of 188 
two specific mutations by 2103 / 181wt K N Y Cp µ→ = . More generally, the probability that a 189 
certain transition by mutation from some strain j  to some strain i  occurs during reverse 190 
transcription j ip → , is given by: 191 
 
( , ) ( , )
= (1 ) ,h i j L h i jj ip µ µ −→ ⋅ −  (5) 192 
where ( , )h i j  denotes the hamming distance (the number of differences) between strain 193 
j  and strain i . All mutation probabilities for the utilized model are depicted in Figure 2 B. 194 
Coupling of Viral Dynamics with NVP Pharmacokinetics: 195 
The efficacy of the non-nucleoside reverse transcriptase inhibitor NVP (1 ( , ))i tη−  at time 196 
t  against strain i  was implemented using the standard maxE -model: 197 
 
50
1(1 ( , )) = ( )1
IC ( )
i t C t
i
η−
+
 (6) 198 
where ( )C t  denotes the NVP concentration at time t  (derived during PK analysis, see 199 
above) and 50IC ( )i  denotes the strain-specific fifty percent inhibitory concentration (see 200 
Figure 2 C). The strain specific infection rate constant under treatment was given by 201 
( , ) = (1 ( , )) (1 ( )) ( , ) SF(t)i t i t s i wtβ η β φ− ⋅ − ⋅ ⋅ , where ( , )wtβ φ  denotes the infection rate 202 
constant of the wild type wt  in the absence of drug φ  (given in Table 1) and ( )s i , 203 
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denotes the fitness loss (e.g., loss in the activity of reverse transcriptase) relative to the 204 
wild type (shown in Figure 2 C). The scaling factor SF(t)  corrects the infection rate β  for 205 
the differences in target cell concentration between mother (reference target cell 206 
concentration) and uninfected newborn. SF(t)  was considered to be time-dependent for 207 
newborns due to immune system development and growth (see Equation S3 and Figure 208 
S1 of the supplementary material), whereas it was set to the value of 1 for HIV-1 209 
infected mothers. 210 
Deterministic –Stochastic Hybrid Simulation 211 
The kinetics of biological systems, in which all reactions occur quasi-continuously over 212 
time or involve large numbers of reactants are well approximated by continuous-213 
determistic simulations (by numerical solution of the systems’ ordinary differential 214 
equations). However, the exact kinetics of biological systems which involve rare reaction 215 
events with small numbers of reactants are intrinsically stochastic and are therefore only 216 
poorly approximated by continuous-determistic simulation (62). In our modelling 217 
framework, the process of HIV-1 transmission denotes such an event in which the 218 
outcome is intrinsically stochastic: Either the transmitted virus becomes entirely cleared 219 
by the immune system before establishing stable infection (V  = 0), or it suceeds in 220 
establishing infection (V approaches its steady state). 221 
In order to fully regard the intrinsic stochasticity of rare events in the utilized model (such 222 
as viral challenges) and to allow efficient simulation of quasi-continuous kinetics, we 223 
chose the deterministic-stochastic hybrid simulation approach presented in (1). 224 
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Prediction of HIV-1 Transmission after Intrapartum- and Extended NVP 225 
Prophylaxis 226 
Model simulations were performed starting with the time of the first maternal dose (if no 227 
dose was given, with the time of birth) and continued until 2 years postpartum. The 228 
number of viruses coming into contact with the newborn during delivery and 229 
breastfeeding was modeled as a function of the maternal viral load at the particular time 230 
of the respective viral challenge. The intrapartum virus transmission was modeled in 231 
terms of a single viral challenge at the time of delivery, while virus transmission via 232 
breastfeeding was modeled in terms of repeated viral challenges during the time after 233 
delivery until 2 years postpartum. The probability of a viral challenge during 234 
breastfeeding was assumed to decrease over time (see Figure S2, supplementary 235 
material). Child growth and immune system development were considered 236 
simultaneously to the model simulation (see supplementary text S1 and Figure S1, 237 
supplementary material). If stable infection of the newborns occurred (defined as total 238 
number of viruses 61 10≥ ⋅  in the newborn) the respective simulation was stopped and 239 
the time between birth and child infection was recorded for subsequent evaluation. The 240 
cumulative infection risk 2 years postpartum was assessed by Kaplan-Meier estimates 241 
and an intrauterine transmission probability of 5% (13) was added. All model predictions 242 
are based on 1000 hybrid deterministic-stochastic simulations to ensure statistic 243 
confidence in the results. 244 
We considered four scenarios for sd-NVP: (A: no prophylaxis, B: single postpartum 245 
newborn 2 mg/kg NVP dose, C: single intrapartum maternal 200 mg NVP dose and D: 246 
intrapartum maternal 200 mg NVP dose plus postpartum newborn 2 mg/kg NVP dose). 247 
We took into account the patient characteristics from the Ugandan program for the 248 
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prevention of mother-to-child transmission discussed above, in particular the individual 249 
time intervals between maternal NVP administration and birth; median 5.1 h [range: 0.3-250 
24.8 h] and the time intervals between birth and newborn NVP administration; median 251 
0.9 h [range: 0.1-40.6 h]. 252 
For the extended newborn NVP prophylaxis, we first simulated HIV-1 dynamics with 253 
maternal intrapartum NVP plus one postpartum newborn NVP dose, as described above, 254 
until day 1 after birth, after which we simulated HIV-1 dynamics until 2 years postpartum, 255 
following either 6 weeks (SWEN-study (3, 40)), 14-, 21 weeks, 6 months (HPTN 046-256 
study (11)), 52-, 78- or 104 weeks of daily oral 2 mg/kg NVP administration, taking into 257 
account the pharmacokinetic characteristics of the population in the program for the 258 
prevention of mother-to-child transmission. 259 
Results 260 
Pharmacokinetics of NVP in Pregnant Women/Mothers and Their 261 
Newborns 262 
The estimated PK parameters (using the model in Figure 1 B) are presented in Table 2. 263 
Mother and newborn data were best described by combined 1-compartment models with 264 
first-order absorption and elimination processes. Since the bioavailability of the oral dose 265 
was unknown, the estimated PK parameters have to be reported as relative parameters. 266 
The relative volume of distribution of mother data, V2/F was estimated to be 90.9 L and 267 
the relative NVP clearance to be 1.22 L/h. Inter-individual variabilities (IIV) were 268 
implemented for all structural parameters relating to mother data and estimated to be 269 
moderate (34% and 33% coefficient of variation (CV) for V2/F and CL1/F, respectively) 270 
but high for KA (160% CV). The placenta clearance PCL/F was estimated to be 111 L/h 271 
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suggesting a rapid placental transfer. The partition coefficient between NVP 272 
concentrations of fetus and pregnant women (PCM) was quantified to be 1.38. The large 273 
volume of distribution and low elimination capacity resulted in a long half-life of 52 h for 274 
mothers. The relative volume of distribution V4/F for newborns was estimated to be 275 
20.0 L and the relative clearance CL2/F to be 0.21 L/h. The half-life of NVP in newborns 276 
was 66 h. 277 
The residual variability was best described using separate proportional error models for 278 
maternal and newborn data, respectively. The proportional error was moderate (27% CV) 279 
for mother and higher (49% CV) for newborn data. The precision of the estimated PK 280 
parameters was sufficient with RSE < 20.5% for fixed-effects and RSE < 33% for 281 
random-effects parameters. The goodness of the final PK model was demonstrated by 282 
GOF plots for observed versus model-predicted NVP concentrations. Overall data 283 
spread around the line of identity suggesting adequate goodness of the PK model (see 284 
supplementary Figure S3). 285 
HIV-1 Transmission Risk under various NVP Single Dose Prophylaxis 286 
Scenarios 287 
During the program for prevention of mother-to-child transmission in Uganda (29), NVP 288 
was administered once to pregnant women during labor and once to newborns shortly 289 
after delivery, with the aim of lowering the transmission probability of HIV-1 from mother-290 
to-child. The results and model-predicted HIV-1 transmission probabilities under the four 291 
sd-NVP prophylaxis scenarios are illustrated in Figure 3 (A: no NVP prophylaxis, B: 292 
single postpartum newborn NVP dose, C: single intrapartum maternal NVP dose and D: 293 
intrapartum maternal NVP dose plus postpartum newborn NVP dose). The model-294 
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predicted transmission risks agreed very well with published data from various trials (3, 295 
20, 28, 36, 40, 50-51, 61). Without prophylaxis, the estimated HIV-1 transmission 296 
probability after 2 years was 37.5 ± 2.9% (Figure 3 A). A single postpartum newborn 297 
dose reduced the transmission probability to 31.7 ± 2.7% (Figure 3 B) whereas a single 298 
intrapartum maternal dose lowered the transmission probability substantially to 20.5 299 
± 2.3% (Figure 3 C). The combination of maternal and newborn doses reduced the 300 
transmission probability to 22.3 ± 2.4% (Figure 3 D), which is insignificantly different 301 
from a single maternal dose alone. The intrapartum infection risk (typically assessed 302 
2 weeks after birth) was 17.7 ± 2.4%, 14 ± 2.1%, 2.3 ± 0.9% and 2.4 ± 0.9% for the four 303 
investigated regimens. From the shape of the curves in Figure 3 A-D it can also be seen 304 
that the subsequent risk of HIV-1 transmission (mainly through breastfeeding) is highest 305 
during the first 200 days after birth. 306 
Mechanism of Prevention of Intrapartum HIV-1 Transmission by Maternal 307 
NVP Prophylaxis 308 
Our data indicate that maternal NVP single dose alone decreases the transmission risk 309 
of HIV-1 substantially compared to newborn NVP dose alone (compare Figure 3B with 310 
3C). Hence, we elucidated the mechanisms by which the maternal NVP dose lowers 311 
HIV-1 transmission probabilities. 312 
The dynamics of viral load decay in the HIV-1 infected mother after the maternal NVP 313 
dose are shown in Figure 4 A. The viral load declined by less than a factor of two during 314 
the first 30 h after single dose NVP. However, the child was born within a range of 0.3-315 
24.8 h, median: 5.1 h (29) (dashed horizontal bar and the open circle in Figure 4 A), 316 
 16 
indicating that the maternal dose had little or no effect on the number of virions that 317 
come in contact with the newborn during intrapartum virus challenge. 318 
In Figure 4 B the concentrations of NVP in a representative newborn from the PK 319 
investigation are depicted at the time of delivery (intrapartum challenge). Since NVP is 320 
known to cross the placenta (37, 39) and this process was quantified by us (PCL, PCM, 321 
see above), a fraction of the maternal NVP concentration was present in the newborn at 322 
the time of delivery, where it is able to prevent the HI-virus from infecting cells (Figure 323 
4B) by lowering the infection rate β  (see Methods section). 324 
Predictors for Selection and Persistence of NVP-resistant HIV-1 Strains in 325 
Mothers after NVP Single Dose Administration 326 
Previous studies reported that a single dose of NVP can already select drug resistant 327 
viral strains in the HIV-1 infected mothers (18, 23), compromising subsequent maternal 328 
treatment success (9, 26, 30) and potentially promoting the transmission of NVP 329 
resistant strains to the child during subsequent breastfeeding. We wanted to assess 330 
predictors for the selection of drug resistant strains in HIV-1 infected mothers, which 331 
might subsequently lead to the transmission of resistant virus to the breastfed child. Our 332 
model predictions revealed a strong correlation between the individual half-life of NVP in 333 
mothers and the duration in which NVP-resistant strains dominated the viral population 334 
in the HIV-1 infected mothers after a single intrapartum maternal NVP dose, see Figure 335 
5 A (spearman’s rank correlation coefficient 2 0.98Sr = ). The model-predicted dynamics of 336 
resistance appearance and fading for some representative mothers are shown in Figure 337 
5 B-E. Our model predictions indicate that depending on the individual pharmacokinetics 338 
of NVP, NVP-resistant strains become selected and might subsequently dominate the 339 
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virus population until NVP will be eliminated and resistant virus will be outgrown by the 340 
wild type (see Figure 5 B-E) once again. This has important implications on the 341 
probability that resistance is transmitted from mother to child and on the success of 342 
subsequent extended newborn NVP prophylaxis. 343 
We derived the following equation to clarify the relation between individual NVP 344 
concentrations C  and resistance selection (derivation is given in supplementary text S2, 345 
supplementary material): 346 
( )
50
50
IC (wt)  (res)
 > ,11- (res)
IC
resistance selection if :
sC
s
K
⋅
−
 (7) 347 
where 50IC (wt) , (res)s  and 50ICK  are the fifty percent inhibitory NVP concentration of the 348 
wild type, the selective disadvantage of the drug resistant viral strain and the fold 349 
increase in the fifty percent inhibitory NVP concentration, respectively. For mutant 350 
K103N, Y181C and the double mutant (K103N/Y181C), the minimum NVP 351 
concentrations which favor their selection are 3.36 ng/mL, 15.5 ng/mL and 25.5 ng/mL, 352 
respectively, based on the phenotypic parameters used in this work ( 50IC (wt) , (res)s  and 353 
50ICK ). 354 
This indicates, that single-point mutations are already selected at concentrations below 355 
the 50IC value of the wild type (23 ng/mL (35)), which can persist in the plasma of the 356 
mother for several weeks after sd-NVP, depending on the individual pharmacokinetic 357 
NVP concentration-time profile. More importantly, if transmission of HIV-1 from mother-358 
to-child occurs during the particular time frame when the resistant virus dominates, it will 359 
likely involve resistant virus and therefore lead to resistance spread. 360 
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Extended NVP Prophylaxis Strategies to Prevent HIV-1 Transmission via 361 
Breastfeeding 362 
We explored the impact of extended newborn NVP prophylaxis on HIV-1 transmission 363 
risk in order to evaluate whether these may, similar to pre-exposure viral prophylaxis, 364 
decrease the probability that viral challenges lead to infection in breastfed infants. In 365 
addition to the maternal dose, we analyzed the impact of 6 weeks (SWEN-study, [17-366 
18]), 14-, 21 weeks, 6 month (HPTN 046-study, [19]), 52-, 78- or 104 weeks of extended 367 
newborn NVP 2 mg/kg dosing, on the transmission risk of HIV-1. The predictions for 368 
6 weeks and 6 months extended newborn NVP are displayed in Figure 6 A and Figure 369 
6 B, respectively, together with clinical data from the SWEN-study (3, 40) (6 weeks 370 
extended NVP) and the HPTN 046 trial (11) (6 month extended NVP). The agreement 371 
between predicted- and observed transmission probabilities was very good. The 372 
cumulative HIV-1 transmission risk 2 years postpartum, in the case of 6-, 14-, 21 weeks, 373 
6 month, 52-, 78- or 104 weeks of extended NVP dosing were 18.5% ± 2.1%, 16.1% 374 
± 1.9%, 14.9% ± 1.9%, 14.3% ± 1.8%, 12.5% ± 1.6%, 8.6% ± 1.2% and 7.0% ± 0.9%, 375 
respectively (see Figure 6 C): All extended NVP regimen significantly reduced HIV-1 376 
transmission during 2 years postpartum, compared to intrapartum single dose 377 
maternal/newborn NVP (cross-tab 2χ  test, p < 0.05, respectively). Notably, the 52- and 378 
104 weeks regimens reduced the risk of transmission by further 50% and 70% 379 
compared to intrapartum maternal/newborn NVP dose alone. The reduction of HIV-1 380 
transmission per week extended NVP was 0.63%, 0.44%, 0.35%, 0.31%, 0.19%, 0.18% 381 
and 0.15% for the 6-, 14-, 21 weeks, 6 months, 52-, 78- or 104 weeks regimens, 382 
respectively, indicating a decline in effectiveness of extended NVP regimens. 383 
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Probability of Transmitting Resistant Virus during Extended NVP 384 
Prophylaxis 385 
The proportion of infections with NVP-resistant virus among the newborns that became 386 
infected 0 2(res. | inf .) yP −  for the entire evaluation period (2 years postpartum) was 387 
19.12%, 15.18%, 24%, 20.21%, 32.89%, 51.35% and 100%, respectively, in the 6-, 14-, 388 
21 weeks, 6 months, 52-, 78- or 104 weeks extended NVP regimens (it was 18.1% in 389 
the single dose intrapartum maternal- plus postpartum newborn regimen), neglecting 390 
intrauterine infection. The proportion of infections with NVP-resistant virus among the 391 
infected newborns during weeks 0-6 and > 6 weeks postpartum were 392 
0 6(res. | inf .) 100%wP − = and 6(res. | inf .) 14%wP > = , respectively in the 6 weeks extended 393 
NVP regimen, which is in good agreement with published data from the SWEN study 394 
( 0 6(res. | inf .) 92%wP − = and 6(res. | inf .) 15%wP > = , respectively (38)). For a single maternal 395 
and newborn NVP dose, the conditional probabilities were 0 6(res. | inf .) 32%wP − = and 396 
6(res. | inf .) 13%wP > = , which is also in good agreement with published data 397 
( 0 6(res. | inf .) 38%wP − = and 6(res. | inf .) 15%wP > = , respectively (38)). The total number of 398 
infant infected with resistant virus during the breastfeeding period (res. | inf .) (inf .)P P⋅ was 399 
not significantly different in any extended newborn NVP regimen (2.58%, 1.68%, 2.38%, 400 
1.88%, 2.47%, 1.85% and 2.00%, respectively in the 6-, 14-, 21 weeks, 6 month, 52-, 401 
78- or 104 weeks regimens, neglecting intrauterine infection) and was slightly lower than 402 
in the single dose intrapartum maternal- plus postpartum newborn regimen (3.18%). Our 403 
results indicated that extended NVP only allows infection with resistant virus during the 404 
duration of its administration. Our predictions also indicated that all infections with 405 
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resistant virus occurred before 200 days postpartum in agreement with resistance 406 
domination in the breastfeeding mothers (shown in Figure 5). 407 
Discussion 408 
Short-course NVP prophylaxis is still widely used in resource-constrained settings to 409 
prevent mother-to-child transmission of HIV-1. Since pregnant women and their 410 
newborns represent particular subpopulations, plasma of mothers and newborns were 411 
sampled for PK investigation during a Ugandan program for the prevention of mother-to-412 
child transmission, which comprised sd-NVP to pregnant women and newborns each. 413 
For PK analysis of the NVP data, a combined population PK model was developed and 414 
subsequently incorporated into pharmacodynamic (PD) investigations. 415 
We found, in agreement with similar studies (4, 12, 14, 29), that a one-compartment 416 
model with first-order absorption and elimination processes was sufficient to describe 417 
the pharmacokinetics of NVP in pregnant women/mothers and newborns. Based on our 418 
previously published separated PK models for pregnant women/mothers and newborns 419 
(29), we developed a combined PK model in the present work that simultaneously 420 
analyzed the NVP concentrations of pregnant women/mothers and newborns. Before 421 
delivery, the PK model constituted the structure of a two-compartment model, where the 422 
central- and peripheral compartments were linked to the pregnant women/mothers and 423 
the fetus, respectively. Utilizing this model structure, we were able to estimate the 424 
plasma/placenta transfer of NVP as newborns presented measureable NVP plasma 425 
concentrations before receiving their own NVP dose. After delivery the combined PK 426 
model for pregnant women/mothers and fetus was separated into two one-compartment 427 
models for mothers and newborns, respectively. All PK parameters were precisely 428 
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estimated as shown by small relative standard errors. The estimated relative volume of 429 
distribution in mothers was very high (V2/F = 91 L) and in excellent agreement with 430 
previously published values (range: 77-106 L) (4, 14, 27, 39). Maternal NVP elimination 431 
capacity was low (CL1/F = 1.22 L/h) and within the range of previously published values 432 
(1.23-1.42 L/h) (4, 12, 39). The calculated half-life of NVP in mothers was 52 h, being 433 
also within the range of previously published values 43-61 h (4, 12, 39). The half-life in 434 
newborns (66 h) was slightly longer than the published value of 47 h (39), but 435 
considerably shorter than the value of 110 h, observed in (4). However, in the previous 436 
study (4), newborn plasma was only sampled over a very short interval (0-50 h), 437 
whereas data in our investigation was sampled over a considerably longer period of time 438 
(0-420 h), allowing to more accurately determine the elimination of NVP in newborns. 439 
The evaluation of the final combined PK model by GOF plots and VPC demonstrated 440 
appropriateness and sufficient predictive performance. Hence, the PK model could be 441 
used as an input for further PD investigations. In order to simultaneously analyze the 442 
impact of NVP pharmacokinetics on HIV-1 acquisition in the newborn, we developed a 443 
PK-coupled stochastic HIV-1 dynamics model. Models for HIV-1 dynamics in 444 
asymptomatically infected individuals are rather established (reviewed in (42)). Few in 445 
silico studies have linked viral dynamics to pharmacokinetics (16, 22, 46), modeled the 446 
impact of pharmacokinetics on the emergence of drug resistance (55), or considered the 447 
dynamics of HIV-1 infection (52-53). However, all these aspects, which concurrently 448 
occur in vivo, have, to the authors´ knowledge, never been addressed simultaneously by 449 
mathematical modeling. In this study, we combined all these aspects in a single model. 450 
Furthermore, our model considers many aspects of child growth, immune system 451 
development and the characteristics of viral challenge during delivery and breastfeeding, 452 
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which have been validated with external data (see Figure S1, supplementary material). 453 
Although no parameter adjustments for the HIV-1 dynamics model have been performed, 454 
model-predicted HIV-1 transmission rates under various NVP-based treatment scenarios 455 
were in excellent agreement with data from nine independent studies (see Figure 3 and 456 
Figure 6), confirming the validity of the chosen approach. 457 
Throughout this work, a reduced virus dynamics model was used, which is suited to 458 
accurately predict viral load decay in HIV-1 infected individuals following single dose 459 
administration of NVP and to predict the subsequent risk of child infection. In the case of 460 
multiple dose maternal drug administration, we recommend to use a model that can 461 
capture all phases of viral load decline, e.g. (56). In the present analysis we did not 462 
focus on viral load dynamics after the infection of the child, but rather focused on the 463 
infection risk (respective simulations were stopped, if newborn infection occurred). For 464 
accurately analyzing viral load dynamics in infected children, we also recommend to use 465 
more elaborated viral dynamics models, e.g. (56). 466 
Our predictions indicated a significant impact of maternal NVP administration on the 467 
reduction of HIV-1 transmission to the newborn (see Figure 3 C). An analysis of the HIV-468 
1 dynamics in the pregnant women between the period of NVP administration and 469 
delivery indicated that the effect of maternal NVP on intrapartum transmission was not 470 
due to a reduction in the number of virus particles potentially coming into contact with 471 
the newborn during delivery, since viral load decayed only by less than a factor of two 472 
during the first 30 h after NVP administration (see Figure 4A). This model-derived result 473 
is confirmed by clinically observed delays in virus load decline for NVP monotherapy 474 
(24-48 h (21)). Likewise, delays in the onset of viral decay have been observed in the 475 
case of ritonavir monotherapy (~30 h (43)) and under highly active antiretroviral therapy 476 
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(HAART) (~18 h (32)). We therefore conclude that a maternal dose, administered at the 477 
onset of labor, may hardly have an impact of the number of viruses that come into 478 
contact with the newborn during delivery. Instead, the PK analysis coupled to the virus 479 
dynamics model, revealed that the main effect of the maternal dose is to provide 480 
potentially protective NVP concentrations via trans-placenta transport to the newborn at 481 
the moment of virus contact during delivery (see Figure 4 B), subsequently preventing 482 
HIV-1 infection. These finding were confirmed by rapid NVP exchange through the 483 
placenta (as indicated by the exchange parameters PCL, PCM in Table 2 and the almost 484 
identical time points of maximum concentrations ( maxt ) values in maternal and newborn 485 
plasma and cord blood (4)). This mechanism of HIV-1 transmission prevention provided 486 
by the maternal single dosing is highly similar to a pre-exposure prophylaxis, which has 487 
recently demonstrated high potential in reducing HIV-1 transmission in the context of 488 
sexual HIV-1 transmission (19). This particular mechanism of HIV-1 prevention by 489 
maternal sd-NVP has important implications for the timing of the maternal dose: Since 490 
trans-placental exchange is rapid (4), the newborn’s NVP concentrations during delivery 491 
would offer maximal protective effect at max (mother)t  of 3.5 h [range: 3.0-4.1 h] 492 
(calculated from individual PK parameter estimates). While NVP is absorbed rapidly (10), 493 
HIV-1 prevention by the maternal dose is likely suboptimal before max (mother)t . The 494 
protective effect however lasts for relatively long periods of time, since NVP is slowly 495 
eliminated (4, 10, 29) (see also Table 2). This indicates that the maternal NVP 496 
administration at the onset of labor might be most effective, if feasible. 497 
A single dose of NVP can select drug resistant viral strains in the HIV-infected mothers 498 
(18, 23) (see Figure 5) and lead to transmission of NVP resistant strains to the child (e.g. 499 
via breastfeeding). Pooled estimates showed that 36% (19–76%) of women have 500 
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detectable NVP resistance mutations 6–8 weeks after exposure to a single dose of NVP 501 
(2). Our model slightly overestimated resistance development in the mothers after 502 
receiving a single intrapartum NVP dose (38% and 63% at week 8 if the detection limit 503 
for resistance was 50% and 20% respectively). This overestimation can be partially 504 
explained by the use of a simplified model of resistance development in our 505 
computational study, which ignores the genetic background on which resistance 506 
develops; e.g. if resistance develops on some viral strain, which is particularly unfit, then 507 
the resistance is less likely to be selected, see parameter (res)s  in Equation (7). Instead, 508 
in order to reduce the complexity of our mathematical model (and to reduce the 509 
computational cost), we assumed that all susceptible viral strains were as fit as the 510 
wild type and therefore all viral strains that develop a particular mutation (K103N, Y181C 511 
and K103N/Y181C) were only assigned a fitness loss that comes from the resistance 512 
mutation and not from the genetic background of the founder strain. In future, more 513 
realistic and computationally feasible solutions for this problem should be developed. 514 
Nevertheless, our estimates of resistance transmission to the newborns/infants were in 515 
good agreement with clinical data from the SWEN study (38). 516 
Our model predictions suggested a correlation between the individual half-life of NVP in 517 
mothers and the duration in which NVP-resistant strains dominated the viral population 518 
in the HIV-1 infected mothers after a single intrapartum maternal NVP dose. Selection of 519 
resistant strains could be explained by a simple mathematical formula (see Equation (7) 520 
and supplementary material) and minimum concentrations for the selection of NVP-521 
resistant strains were derived. Combining the pharmacokinetic analysis of individual 522 
pharmacokinetics with the model of HIV-1 dynamics and transmission, we predicted that 523 
transmission of NVP-resistant strains would occur during the first 200 days after single 524 
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dose maternal NVP, in line with the time frame in which resistant strains likely dominate 525 
the viral population (Figure 5). The observed correlation of NVP half-life and resistance 526 
selection suggests that resistance selection and transmission could potentially be 527 
reduced if drugs were administered to the mothers, which exhibit a shorter half-life than 528 
NVP (e.g. zidovudine) and which can cross the placenta as effectively as NVP. Adding 529 
drugs to the maternal sd- NVP is another effective approach to reduce resistance 530 
selection in the HIV-1 infected mothers and to further lower intrapartum transmission 531 
rates (6, 8, 34), potentially by increasing the genetic barrier to resistance selection. A 532 
thorough understanding of the underlying mechanisms, however, is still lacking and 533 
mathematical models including combinations of drugs for elucidation remain to be 534 
developed in future. 535 
Currently, two main strategies are pursued in order to reduce subsequent HIV-1 536 
transmission via breastfeeding: (i) maternal ART or (ii) extended newborn NVP 537 
prophylaxis. Maternal ART has been shown to reduce HIV-1 transmission via 538 
breastfeeding, by lowering maternal viral load to less than 400 copies per mL (15, 48), 539 
but long-term drug treatment might not be available in resource-limited settings. 540 
Extended newborn NVP administration has been suggested to reduce the transmission 541 
risk of HIV-1 by postpartum breastfeeding and might be the regimen of choice in 542 
extremely resource-limited settings for reasons of cost-effectiveness compared to 543 
maternal ART (59). In Figure 6, we analyzed the impact of 6-, 14-, 21 weeks, 6 month, 544 
52-, 78- or 104 weeks extended newborn NVP on the transmission risk of HIV-1. Our 545 
data agrees very well with published data from the SWEN-study (3, 40) (6 weeks 546 
extended NVP) and the HPTN 049-study (11) (6 month extended NVP). Our results 547 
indicate that a significant reduction in the HIV-1 transmission 2 years postpartum could 548 
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be achieved for all investigated extended NVP regimens, in comparison to single dose 549 
intrapartum maternal and newborn NVP dose alone. The cost-effectiveness however 550 
decreases with increasing length of extended NVP as reflected by the reduction of HIV-1 551 
transmission per week of extended newborn NVP from 0.63% (6 weeks of extended 552 
NVP) to 0.15% (104 weeks of NVP). This indicates that although substantial further 553 
decrease of HIV-1 transmission could be achieved by extended NVP regimens, shorter 554 
periods of extended NVP might be more feasible in (extremely) resource-limited settings 555 
with regard to cost-effectiveness. Our estimates of resistance transmission to the 556 
newborns were in good agreement with clinical data from the SWEN-study (38). Overall, 557 
our results indicated an increase in the proportion of infections with resistant virus for 558 
longer durations of extended NVP prophylaxis. However, as extended NVP 559 
simultaneously minimizes the transmission probability the total number of newborns, 560 
which become infected with resistant virus was not increased by any of the extended 561 
NVP prophylaxis regimens compared to NVP single dose. 562 
Summarized, we have developed a coupled in vitro/in vivo pharmacokinetic-563 
pharmacodynamic model to assess the effects of distinct NVP prophyalxis regimens on 564 
the prevention of mother-to-child transmission of HIV-1 and resistance formation. Our 565 
model shows very good predictive performance compared to data from clinical studies. 566 
The model may be adapted to predict the outcome of other drug interventions and could 567 
therefore be used as a supportive tool to improve HIV-1 prevention, maximize cost-568 
effectiveness and reduce risk of resistance selection when novel studies are planned. 569 
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Legends 822 
Figure 1: Final PK model of mother and newborn data. A: Observed NVP concentrations 823 
in the plasma of HIV-1 infected pregnant women/mothers (filled diamonds) and in the 824 
plasma of newborns (open triangles) sampled over three time periods: delivery, week 1 825 
and week 2 after single dose of 200 mg NVP for pregnant women and 2 mg/kg NVP 826 
administered to newborns (modified from (29)). B: Schematic structural model for the PK 827 
of mothers and newborns. The absorption rate constant for oral dose of mothers and 828 
newborns are KA and K34, respectively. V2 describes the central volume of distribution 829 
for maternal data. V4 equals the volume of distribution of the peripheral compartment 830 
(fetus/newborn compartment). Both compartments were linked by placenta clearance 831 
(PCL) term before delivery. All dashed lines highlight time-dependent processes while 832 
solid lines present continuous processes over the entire investigational period. The 833 
partition coefficient fetus to pregnant women (PCM) denotes the ratio between NVP 834 
concentrations in the fetus and maternal NVP concentrations before delivery and at 835 
 35 
quasi steady state. NVP elimination from the central and the peripheral compartment 836 
was described by CL1 and CL2, respectively. C and D: VPC of the observed NVP 837 
concentrations in maternal plasma (black diamonds, C) and in newborn plasma (open 838 
triangles, D) over time and 5th and 95th percentiles of model simulations and model-839 
simulated median (dashed- and solid lines). 840 
Figure 2: Mathematical model of virus dynamics, mutation and transmission. A: Life-841 
cycle models of HIV-1 in mothers and newborns and their interconnection via 842 
intrapartum- and breastfeeding challenge. Free virus can infect T-cells with infection rate 843 
constant β, which encompasses all steps from target cell binding, fusion, to reverse 844 
transcription. Early infected T-cells (after reverse transcription but prior to pro-virus 845 
integration) become transformed into productively infected cells T2, after pro-virus 846 
translocation into the nucleus and integration with rate kT. Productively infected T-cells 847 
T2 produce new virus V with rate N. Mutation occurs during the process of reverse 848 
transcription (embodied in parameter β). NVP inhibits reverse transcription and therefore 849 
affects parameter β in our model. All parameter values are listed in Table 1. Intrapartum 850 
viral challenge occurs during delivery, whereas breastfeeding viral challenges occur 851 
repeatedly after birth until the age of 2 years, according to the breastfeeding frequency 852 
(Figure S2, supplementary material). B: Mutational graph showing the transition 853 
probabilities j ip →  between the four virus strains (wild type wt and 3 mutants K103N, 854 
Y181C and K103N/Y181C) considered here. C: Phenotypic attributes of the four 855 
mutants. The extension of the bars to the right illustrates their IC50 value, whereas the 856 
left extension indicates their fitness loss. The IC50 values were 23 ng/mL (35) (corrected 857 
for protein binding (5)), 1265 ng/mL (45), 3703 ng/mL and >11500 ng/mL (45) for wt, the 858 
K103N, the Y181C mutation and the double mutant K103N/Y181C, respectively. The 859 
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selective disadvantage s with respect to the wild type was 12.5%, 40% and 52.5% for 860 
the K103N, the Y181C mutation and the double mutant (33). 861 
Figure 3: Cumulative HIV-1 transmission risk under various NVP single dose prophylaxis 862 
strategies. Solid lines denote the Kaplan-Meier estimates of the model-predicted 863 
cumulative probability of infection whereas light-grey areas represent the confidence 864 
range for the model predictions. A: no NVP is given (upward- and downward pointing 865 
triangles denote data from (61) and (36)); B: a single postpartum NVP dose (2 mg/kg) is 866 
given to the newborn within 72 h after birth (squares denote data from (51)); C: a single 867 
intrapartum NVP dose (200 mg) is given to the mother at the onset of labor; D: a single 868 
intrapartum NVP dose (200 mg) and a single postpartum newborn dose (2 mg/kg) were 869 
administered (crosses, open circles, diamonds, filled circles and plus signs denote data 870 
from (3, 20, 28, 40, 50)). In all simulations, an intrauterine transmission probability of 5% 871 
(13) was assumed. 872 
Figure 4: A: Viral load (thick line) during the first 30 h in the plasma of HIV-1 infected 873 
pregnant women/mothers after a single intrapartum dose NVP in relation to the time of 874 
delivery (open circle denotes the median time of delivery, see Methods section and 875 
dashed horizontal bar denotes the range). B: NVP concentration in a representative 876 
newborn from the PK-investigation before- during- and after birth (solid line). The black 877 
square and the black circle indicate the time of birth and the time of the newborn NVP 878 
single oral dose in the representative newborn, respectively. 879 
Figure 5: Predicted correlation between NVP elimination and persistence of NVP 880 
resistance in HIV-1 positive mothers after a single dose of NVP. A: Correlation of 881 
individual NVP half-life and predicted duration in which NVP resistance dominated the 882 
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viral population in mothers. B-E: Examples of resistance appearance and fading in 883 
distinct, representative HIV-1 positive mothers after single dose NVP administration at 884 
the onset of labor. Solid line: relative wild type abundance, dashed line: relative 885 
abundance of NVP resistant strains. The respective half-life of NVP in the distinct 886 
representative mothers was 1.3, 2.1, 2.2 and 3.6 days for panels B-E. 887 
Figure 6: HIV-1 transmission risk in the case of extended newborn NVP dosing. 888 
A: Predicted transmission risk after 6 weeks extended NVP treatment (solid line) and 889 
confidence range (light-grey area) together with clinical data from the SWEN-study (3, 890 
40) (open circles). B: Predicted transmission risk after 6 month extended NVP treatment 891 
(solid line) and confidence range (light-grey area) together with clinical data from the 892 
HPTN 046-study (11) (open squares). The intrauterine transmission risk was assumed 893 
to be 5% (13). C: Predicted transmission risk after 2 years, in the case of no prophylaxis, 894 
a single dose maternal and newborn NVP dose, 6-, 14-, 21 weeks, 6 month, 52-, 78- or 895 
104 weeks of extended newborn NVP in addition to a single intrapartum maternal NVP 896 
dose. 897 
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Tables 898 
Table 1: Virus dynamics parameters. All units in [1/day], except the point mutation 899 
probability µ  in [1/rev. transcr./base], the infection rate constant ( , )wtβ φ in [1/virions/day] 900 
and the T-cell production λ  [cells/day/kg body weight].  901 
Parameter Value Reference 
Tk  0.35 (63) 
2Tδ  1 (32) 
N  1000 (47) 
µ  2.16·105 (31) 
1,T Tδ δ  0.02 (47) 
( , )wtβ φ  8·10-12  (47) 
PICδ  0.35 (56) 
λ (newborn) Eq. S2§  
CLV (newborn) Eq. S4§  
λ (mother) 2.86·107 * (57) 
CLV (mother) 23 (32) 
*The maternal zero-order T-cell production of 92 10⋅ (57) was divided by the weight (70 kg) 902 
of the patients in (57), to yield the parameter stated in the table. § see supplementary 903 
text S1. 904 
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Table 2: Population PK estimates of NVP of the final combined PK model for mothers 905 
and newborns. 906 
Model parameters Units Population estimates RSEa, % 
FIXED EFFECTS 
  
KA [h-1] 1.34 fixed - 
V2/F [L] 90.9 5.85 
CL1/F [L·h-1] 1.22 6.33 
V4/F [L] 20.0 18.6 
CL2/F [L·h-1] 0.21 16.1 
K34 [h-1] 1.34 fixed - 
PCL/F [L·h-1] 111.0 20.5 
PCM  1.38 7.68 
RANDOM EFFECTS 
  
Interindividual Variability 
  
ωKA [% CV] 159.7 30.3 
ωCL1/F [% CV] 32.9 25.7 
ωV2/F [% CV] 34.1 33.1 
Residual Variability 
  
σ proportional (mothers) [% CV] 27.2 10.6 
σ proportional (newborns) [% CV] 49.1 11.0 
a
 Relative standard error (standard error divided by population estimate ·100; 907 
for the random effects parameters RSE is related to the corresponding variance scale). 908 
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F i g u r e 1 : F i n a l P K m o d e l o f m o t h e r a n d n e w b o r n d a t a . A : O b s e r v e d N V P c o n c e n t r a t i o n s i n t h e p l a s m a o f
H I V Â 1 i n f e c t e d p r e g n a n t w o m e n / m o t h e r s ( f i l l e d d i a m o n d s ) a n d i n t h e p l a s m a o f n e w b o r n s ( o p e n t r i a n g l e s )
s a m p l e d o v e r t h r e e t i m e p e r i o d s : d e l i v e r y , w e e k 1 a n d w e e k 2 a f t e r s i n g l e d o s e o f 2 0 0 m g N V P f o r
p r e g n a n t w o m e n a n d 2 m g / k g N V P a d m i n i s t e r e d t o n e w b o r n s ( m o d i f i e d f r o m ( 2 9 ) ) . B : S c h e m a t i c s t r u c t u r a l
m o d e l f o r t h e P K o f m o t h e r s a n d n e w b o r n s . T h e a b s o r p t i o n r a t e c o n s t a n t f o r o r a l d o s e o f m o t h e r s a n d
n e w b o r n s a r e K A a n d K 3 4 , r e s p e c t i v e l y . V 2 d e s c r i b e s t h e c e n t r a l v o l u m e o f d i s t r i b u t i o n f o r m a t e r n a l d a t a .
V 4 e q u a l s t h e v o l u m e o f d i s t r i b u t i o n o f t h e p e r i p h e r a l c o m p a r t m e n t ( f e t u s / n e w b o r n c o m p a r t m e n t ) . B o t h
c o m p a r t m e n t s w e r e l i n k e d b y p l a c e n t a c l e a r a n c e ( P C L ) t e r m b e f o r e d e l i v e r y . A l l d a s h e d l i n e s h i g h l i g h t
t i m e Â d e p e n d e n t p r o c e s s e s w h i l e s o l i d l i n e s p r e s e n t c o n t i n u o u s p r o c e s s e s o v e r t h e e n t i r e i n v e s t i g a t i o n a l
p e r i o d . T h e p a r t i t i o n c o e f f i c i e n t f e t u s t o p r e g n a n t w o m e n ( P C M ) d e n o t e s t h e r a t i o b e t w e e n N V P c o n c e n t r a Â
t i o n s i n t h e f e t u s a n d m a t e r n a l N V P c o n c e n t r a t i o n s b e f o r e d e l i v e r y a n d a t q u a s i s t e a d y s t a t e . N V P e l i m i n a Â
t i o n f r o m t h e c e n t r a l a n d t h e p e r i p h e r a l c o m p a r t m e n t w a s d e s c r i b e d b y C L 1 a n d C L 2 , r e s p e c t i v e l y . C a n d
D : V P C o f t h e o b s e r v e d N V P c o n c e n t r a t i o n s i n m a t e r n a l p l a s m a ( b l a c k d i a m o n d s , C ) a n d i n n e w b o r n
p l a s m a ( o p e n t r i a n g l e s , D ) o v e r t i m e a n d 5 t h a n d 9 5 t h p e r c e n t i l e s o f m o d e l s i m u l a t i o n s a n d m o d e l Â
s i m u l a t e d m e d i a n ( d a s h e d Â a n d s o l i d l i n e s ) .
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F i g u r e 3 : C u m u l a t i v e H I V  1 t r a n s m i s s i o n r i s k u n d e r v a r i o u s N V P s i n g l e d o s e p r o p h y l a x i s s t r a t e g i e s . S o l i d l i n e s
d e n o t e t h e K a p l a n  M e i e r e s t i m a t e s o f t h e m o d e l  p r e d i c t e d c u m u l a t i v e p r o b a b i l i t y o f i n f e c t i o n w h e r e a s l i g h t 
g r e y a r e a s r e p r e s e n t t h e c o n f i d e n c e r a n g e f o r t h e m o d e l p r e d i c t i o n s . A : n o N V P i s g i v e n ( u p w a r d  a n d d o w n 
w a r d p o i n t i n g t r i a n g l e s d e n o t e d a t a f r o m ( 6 1 ) a n d ( 3 6 ) ) ; B : a s i n g l e p o s t p a r t u m N V P d o s e ( 2 m g / k g ) i s g i v e n
t o t h e n e w b o r n w i t h i n 7 2 h a f t e r b i r t h ( s q u a r e s d e n o t e d a t a f r o m ( 5 1 ) ) ; C : a s i n g l e i n t r a p a r t u m N V P d o s e ( 2 0 0
m g ) i s g i v e n t o t h e m o t h e r a t t h e o n s e t o f l a b o r ; D : a s i n g l e i n t r a p a r t u m N V P d o s e ( 2 0 0 m g ) a n d a s i n g l e p o s t 
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( 1 3 ) w a s a s s u m e d .
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F i g u r e 4 : A : V i r a l l o a d ( t h i c k l i n e ) d u r i n g t h e f i r s t 3 0 h i n t h e p l a s m a o f H I V ﬂ 1 i n f e c t e d p r e g n a n t w o m e n / m o t h e r s
a f t e r a s i n g l e i n t r a p a r t u m d o s e N V P i n r e l a t i o n t o t h e t i m e o f d e l i v e r y ( o p e n c i r c l e d e n o t e s t h e m e d i a n t i m e o f
d e l i v e r y , s e e M e t h o d s s e c t i o n a n d d a s h e d h o r i z o n t a l b a r d e n o t e s t h e r a n g e ) . B : N V P c o n c e n t r a t i o n i n a r e p r e ﬂ
s e n t a t i v e n e w b o r n f r o m t h e P K ﬂ i n v e s t i g a t i o n b e f o r e ﬂ d u r i n g ﬂ a n d a f t e r b i r t h ( s o l i d l i n e ) . T h e b l a c k s q u a r e a n d
t h e b l a c k c i r c l e i n d i c a t e t h e t i m e o f b i r t h a n d t h e t i m e o f t h e n e w b o r n N V P s i n g l e o r a l d o s e i n t h e r e p r e s e n t a ﬂ
t i v e n e w b o r n , r e s p e c t i v e l y .
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F i g u r e 5 : P r e d i c t e d c o r r e l a t i o n b e t w e e n N V P e l i m i n a t i o n a n d p e r s i s t e n c e o f N V P r e s i s t a n c e i n H I V  1
p o s i t i v e m o t h e r s a f t e r a s i n g l e d o s e o f N V P . A : C o r r e l a t i o n o f i n d i v i d u a l N V P h a l f  l i f e a n d p r e d i c t e d d u r a t i o n
i n w h i c h N V P r e s i s t a n c e d o m i n a t e d t h e v i r a l p o p u l a t i o n i n m o t h e r s . B  E : E x a m p l e s o f r e s i s t a n c e a p p e a 
r a n c e a n d f a d i n g i n d i s t i n c t , r e p r e s e n t a t i v e H I V  1 p o s i t i v e m o t h e r s a f t e r s i n g l e d o s e N V P a d m i n i s t r a t i o n a t
t h e o n s e t o f l a b o r . S o l i d l i n e : r e l a t i v e w i l d t y p e a b u n d a n c e , d a s h e d l i n e : r e l a t i v e a b u n d a n c e o f N V P r e s i s t a n t
s t r a i n s . T h e r e s p e c t i v e h a l f  l i f e o f N V P i n t h e d i s t i n c t r e p r e s e n t a t i v e m o t h e r s w a s 1 . 3 , 2 . 1 , 2 . 2 a n d 3 . 6 d a y s
f o r p a n e l s B  E .
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F i g u r e 6 : H I V  1 t r a n s m i s s i o n r i s k i n t h e c a s e o f e x t e n d e d n e w b o r n N V P d o s i n g . A : P r e d i c t e d t r a n s m i s s i o n r i s k
a f t e r 6 w e e k s e x t e n d e d N V P t r e a t m e n t ( s o l i d l i n e ) a n d c o n f i d e n c e r a n g e ( l i g h t  g r e y a r e a ) t o g e t h e r w i t h c l i n i c a l
d a t a f r o m t h e S W E N  s t u d y ( 3 , 4 0 ) ( o p e n c i r c l e s ) . B : P r e d i c t e d t r a n s m i s s i o n r i s k a f t e r 6 m o n t h e x t e n d e d N V P
t r e a t m e n t ( s o l i d l i n e ) a n d c o n f i d e n c e r a n g e ( l i g h t  g r e y a r e a ) t o g e t h e r w i t h c l i n i c a l d a t a f r o m t h e H P T N 0 4 6 
s t u d y ( 1 1 ) ( o p e n s q u a r e s ) . T h e i n t r a u t e r i n e t r a n s m i s s i o n r i s k w a s a s s u m e d t o b e 5 % ( 1 3 ) . C : P r e d i c t e d t r a n s 
m i s s i o n r i s k a f t e r 2 y e a r s , i n t h e c a s e o f n o p r o p h y l a x i s , a s i n g l e d o s e m a t e r n a l a n d n e w b o r n N V P d o s e , 6  ,
1 4  , 2 1 w e e k s , 6 m o n t h , 5 2  , 7 8  o r 1 0 4 w e e k s o f e x t e n d e d n e w b o r n N V P i n a d d i t i o n t o a s i n g l e i n t r a p a r t u m
m a t e r n a l N V P d o s e .
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S1 Child Growth, CD4+ Proliferation and Immune System De-
velopment
For the asymptomatically HIV-infected mother, we considered the rates λ(t) and CLV(t) to be time-
invariant (see Table 2, main article). However, for the child, we considered growth and -immune system
development. The body weight BWchild in [kg] of the infants was calculated using the following equation:
BWchild(age) = Kmax ·
age
K50 + age
+ age · r + 3.3 (S1)
with parameters Kmax = 5.5 [kg], K50 = 137.2 [days] and r = 0.0054 [kg/day] derived after fitting
Eq. (S1) to data from the WHO [1] in Fig. S1 A. The parameter λchild(t), which denotes the children’s
proliferation of T-cells, was calculated according to
λchild(age) =
λadult
BWadult
·
(
1 +
Tmax
age + kinact
)
· BWchild(age) (S2)
with parameters λadult = 2 · 10
9 [cells/day] [2] (and assuming an adult body weight of BWadult70 [kg]),
Tmax = 2292 [days] and kinact = 682 [days]. A comparison of predicted CD4
+-counts in uninfected
African children born to HIV infected mothers and data from the literature [3] is shown in Figure S1 B.
The scaling factor SF(t), which corrects the infection rate β for the differences in target cell density
between mother and uninfected child, has been defined as following: SF(t) = Tchild(t)BWchild(t) ·
BWadult
Tadult
. After
substituting Eq. (S2) and approximating T = λ
δT
, we derive
SF(t) =
(
1 +
Tmax
age + kinact
)
. (S3)
Finally, we assumed that the child develops an anti-HIV immune response, as a result of immune
system maturation and as a result of repeated exposure to HIV during breastfeeding [4]. The HIV-
specific response has been modeled in terms of a time-dependent virus clearance CLVchild(age):
CLVchild(age) = age ·
CLV(infected)− CLV(naive)
T50 + age
+ CLV(naive) (S4)
2with T50 = 100 [days]. The parameter CLV(infected) = 23 [1/day] [5] denotes the virus clearance in
an asymptomatically infected adult and CLV(naive) = 2.3 [1/day] [6–8] denotes the virus clearance in a
HIV-naive child.
S2 Minimum NVP Concentration that Selects for Drug Resis-
tance
In this section we will calculate the minimum concentration which selects drug resistance.
The reproductive number [9, 10] R0 denotes the average number of viral particles that are produced
from each virus particle in the parent population. In a rapidly reproducing population, like HIV, this
quantity is equivalent to the fitness of each virus particle. It can be calculated from the parameters in the
presented virus dynamics model (Eq. (1)-(4), main article). In our model, the strain-specific reproductive
numbers are given by:
R0(i, t) =
β(i, t) · T(t) · kT ·N
CLV · (δPIC + kT + δT1) · δT2
(S5)
with β(i, t) = (1 − η(i, t)) · (1 − s(i)) · β(wt, φ). In formula (S5), i denotes the viral strain (wild type,
K103N- Y181C- and K103N/Y181C mutant) and t denotes the time. All parameter definitions are pro-
vided in the main article.
A drug resistant mutant is selected over the wild type, if its fitness (= reproductive number) is greater
than that of the wild type. We therefore derive
selection of res. mutant if: R0(res,t)
R0(wt,t)
> 1. (S6)
Inverting Eq. (S6) and substituting Eq. (S5), we derive
selection of res. mutant if: 1−η(wt,t)(1−s(r))·(1−η(res,t)) < 1. (S7)
After substituting Eq. (6) (main article) and resolving for the concentration of NVP, C(t), we derive
selection of res. mutant if: C(t) >
IC50(wt) · s(res)
(1− s(res))− 1
KIC50
(S8)
where s(res) denotes the selective disadvantage of the mutant (relative to the wild type) and KIC50 =
IC50(res)
IC50(wt)
is the fold increase in IC50 of the mutant strain (see e.g. [11]). Using Eq. (S8) with parameters
for the K103N, the Y181C and the double mutant [11–14], we derive the threshold values provided in
section Correlation of NVP Elimination and Persistence of NVP Resistance in HIV-1 Infected Mothers
after Single Dose Administration (main article).
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Figure S1. A: WHO data [1] (green open circles for boys and blue squares for girls) and prediction
using Eq. (S1) (solid blue line) of weight gain for infants during the first 5 years of age. B: Newborn
immune system development, exemplified for CD4+ count. Solid line: prediction using Eq. (S2). Green
and blue dots: data from [3].
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Figure S2. The probability of viral challenge through breastfeeding was assumed to decrease with
time, as mothers change from exclusive breastfeeding to weaning. Blue bars represent the probability of
virus challenge for a given time interval, relative to the first time interval (shortly after birth).
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Figure S3. Goodness-of-fit Plots. A: Goodness-of-fit for population predicted- versus observed NVP
concentrations. B: Goodness-of-fit for individual predicted versus observed NVP concentrations.
